Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
JBIO
Jade Biosciences, Inc.
NASDAQCM
Biotechnology
United States
$19.94
▲
+0.09 (+0.45%)
OPEN
—
OPEN
$19.94
HIGH
$20.35
LOW
$19.70
PREV CLOSE
$19.85
VOLUME
309.3K
0.30x avg
BID / ASK
14.64 / 25.54
spr 10.90
MARKET CAP
$1.27B
DAY RANGE
$19.70
$20.35
P/E (TTM)
—
Fwd -7.5
EPS (TTM)
-1.07
DIV YIELD
—
52W HIGH
$28.00
-28.8%
52W LOW
$6.91
+188.6%
BETA
—
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
PRE-MARKET
$19.91
+0.06
(+0.30%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
JBIO
$19.94
▲
+0.45%
Chart
Valuation
Financials
Peers
News
JBIO · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
Loading K-line chart…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-ON
253 BARS · +156.3% YOY
1-year price chart. Started at 7.78, currently 19.94, up 156.3 percent. Range 6.95 to 26.85 over 253 data points.
2025-09-04
$7.78 → $19.94 (+156.3%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$24.21
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: strong-sell
· peers $24.21 (+21.4%)
Peers:
REPL
ODTX
ORIC
MGTX PE16
MNKD
JANX
CRVS
GLUE
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
3 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$127.4M
-$94.7M
-$94.9M
$349.8M
2024-12
—
-$47.0M
-$22.6M
—
$72.8M
2023-12
—
-$75.5M
-$56.8M
-$56.9M
$127.4M
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
REPL
ODTX
ORIC
MGTX
MNKD
JANX
CRVS
GLUE
KURA
SANA
NEWS
Recent News (past 14 days)
—
7 HEADLINES · LAST 14 DAYS
Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says
MT Newswires · 2026-09-04
Jade Biosciences to Participate in Upcoming Conferences
GlobeNewswire · 2026-09-01
Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating
MT Newswires · 2026-08-10
Jade Biosciences' Q2 Loss Narrows
MT Newswires · 2026-08-10
Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics
MT Newswires · 2026-07-02
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Insider Monkey · 2026-06-30
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
GlobeNewswire · 2026-06-26